FDA halts approval of blood plasma as COVID-19 treatment

The FDA is holding off on granting emergency situation usage authorization to COVID-19 survivors blood plasma as a prospective treatment for the illness, according to the New York Times.

Several federal public health authorities– consisting of National Institutes of Health Director Francis Collins, MD, PhD, and National Institute of Allergy and Infectious Diseases Director Anthony Fauci, MD– motivated FDA leaders to hold off on licensing making use of blood plasma until there is more definitive data proving its effectiveness in treating COVID-19, the New York Times reported.

. More short articles on pharmacy: AstraZeneca knocked by advocacy group over drug discount rate denialsUS to evaluate benefits of remdesivir with 2nd drugWalgreens, CVS taking extra precautions to deliver influenza shots in the middle of pandemic.

There have actually been no medical trials released in a peer-reviewed journal showing blood plasmas efficiency in dealing with COVID-19. Mayo Clinic is conducting a massive human trial that could produce more definitive information in the near future.

The FDA has actually halted its emergency use permission process as it examines more data, however an approval might still be released in the next couple months if it finds data to prove blood plasmas ability to treat COVID-19, according to the National Institute of Allergy and Infectious Diseasess medical director, H. Clifford Lane, MD

Katie Adams –
Wednesday, August 19th, 2020
Print|Email.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.